Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib neoadjuvant therapy for locally advanced refractory thyroid cancer
ChiCTR2200063411Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in thyroid cancer, well-differentiated thyroid cancer (WDTC) and poorly differentiated thyroid carcinoma (PDTC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Safety of lenvatinib neoadjuvant therapy. Started Sep 2022; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)poorly differentiated thyroid carcinoma (PDTC)
Beyond the preview
Go deeper on ChiCTR2200063411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063411.